Evaluation for the safety of a novel oral Xa inhibitor in combination with chemotherapy in patients with advanced or recurrent colorectal cancer - Evaluation for the safety of a novel oral Xa inhibitor in combination with chemotherapy in patients with advanced or recurrent colorectal cancer

Division of lower GI, department of surgery, Hyogo College of Medicine0 sites50 target enrollmentApril 6, 2021

Overview

Phase: 未知
Intervention: Not specified
Conditions: colorectal cancer
Sponsor: Division of lower GI, department of surgery, Hyogo College of Medicine
Enrollment: 50
Status: Recruiting
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

April 6, 2021

End Date

December 31, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

Division of lower GI, department of surgery, Hyogo College of Medicine

•(1\) Patients who are bleeding (2\) Patients with complications that may cause bleeding 3\) Patients using heparin, low molecular weight heparin, danaparoid, antithrombin (argatroban, etc.), oral anticoagulant (warfarin), thrombolytic, antiplatelet agents (ticlopidine, clopidogrel, aspirin, etc.) Patients who are taking strong inducers or inhibitors of CYP3A4\. (5\) Patients who do not have major organ function. Patients who do not meet any of the following criteria (6\) Patients with a known history of hypersensitivity to any component of the study drug or any drug used in the chemotherapy regimen (7\) Patients with a history of cerebral hemorrhage (viii) Patients with contrast media allergy (9\) Patients with acute bacterial endocarditis (10\) Patients for whom edoxaban cannot be administered according to the package insert (11\) Other patients deemed inappropriate for the study by the principal investigator or sub\-investigator.